In findings that open the door to a completely different approach to curing HIV infections, scientists from the Florida campus of The Scripps Research Institute (TSRI) have for the first time shown that a novel compound effectively suppresses production of the virus in chronically infected cells, and prevents viral rebound, even when those infected cells are subjected to vigorous stimulation.
The study, led by TSRI Associate Professor Susana Valente, was published online Oct. 17 before print in the journal Cell Reports.
“No other anti-retroviral used in the clinic today is able to completely suppress viral production in infected cells in vivo,” Valente said. “When combining this drug with the standard cocktail of anti-retrovirals used to suppress infection in humanized mouse models of HIV-1 infection, our study found a drastic reduction in virus RNA present—it is really the proof-of-concept for a ‘functional cure.’”
Valente, a pioneer in this new approach, calls it “Block-and-Lock”—the approach blocks reactivation of the virus in cells, even during treatment interruptions, and locks HIV into durable state of latency.
Valente and her colleagues use a derivative of a natural compound called didehydro-Cortistatin A (dCA), which blocks replication in HIV-infected cells by inhibiting the viral transcriptional activator, called Tat, halting viral production, reactivation and replenishment of the latent viral reservoir.
“Combining dCA with anti-retroviral therapy accelerates HIV-1 suppression and prevents viral rebound after treatment interruption, even during strong cellular activation,” Valente said. “It’s important to note that our study uses the maximum tolerable dose of the drug—with virtually no side effects.”
The scientists studied the combination therapy in a mouse model of HIV latency and persistence. Once the combined treatment regimen was halted, viral rebound was delayed up to 19 days, compared with just seven days in mouse models receiving only anti-retroviral treatment.
“This demonstrates the potential of ‘block-and-lock’ strategies,” said TSRI Research Associate Cari F. Kessing, co-first author of the study. “This study shows that a ‘functional cure’ approach can succeed in reducing residual virus in the blood during anti-retroviral treatment and limiting viral rebound during treatment interruption.”
“In half of the dCA treated mice, the virus was undetectable for 16 days after all treatment was halted,” said the University of North Carolina’s Christopher Nixon, another first author.
“We blocked Tat, and the cell’s machinery did the rest,” said TSRI Research Associate Chuan Li, a coauthor of the study. “The result was that the HIV promoter becomes repressed.”
Valente pointed out that the animal models were exposed to just a single month of treatment. “That’s a relatively short period of time,” she said. “We think longer treatments will result in longer, or even permanent, rebound delays. The question is how long? We’re studying that now.”
Because any viral rebound of HIV comes with a host of adverse effects, Valente noted, blocking that rebound would automatically reduce those effects.
“This is the only class of drugs that stops infected cells from making viruses outright,” said Valente. “All current antivirals work later in the viral lifecycle, so only a HIV transcriptional inhibitor like dCA can stop the side effects of low-level virus production.”
The Latest on: HIV
- Joburg clinic rolls out HIV self-testing kits to localson November 12, 2019 at 8:46 am
Johannesburg - A non-profit clinic in Johannesburg is rolling out self-screening HIV kits in a bid for more South Africans to know their HIV status. One in five South Africans do not know their HIV ...
- NACA decentralises office, says it’s to strengthen fight against HIV/AIDSon November 12, 2019 at 7:58 am
The Director-General of the National Agency for the Control of HIV/AIDS, Dr. Gambo Aliyu, has said the decentralisation of the agency’s office to the six geopolitical zones of the country is to ...
- An HIV outbreak is tied to homelessness, which also complicates treatment: Morning Briefingon November 11, 2019 at 9:56 pm
HOMELESS WITH HIV: A lack of housing has made a preventable disease deadly in Oregon. People who have homes can fairly easily survive HIV with a daily pill, but it remains a potential death sentence ...
- Will Its HIV Lineup Save Gilead Sciences?on November 11, 2019 at 2:02 pm
The company blamed "competitive dynamics" for the decline in its HCV sales. By contrast, revenues from its HIV products went in the opposite direction, up 13% year over year. It is important to note ...
- He revealed his HIV status to his employer. Then he was fired, a lawsuit alleges.on November 11, 2019 at 1:21 pm
When Armando Gutierrez learned he was HIV-positive last December, he struggled to share the information with his employer. The 31-year-old believed he was well-liked at the Kansas chain restaurant ...
- Computer-Based Training Promising for HIV-Related Cognitive Issueon November 11, 2019 at 9:35 am
PORTLAND, Ore. -- A computerized cognitive training program helped people with HIV and HIV-associated neurocognitive disorder (HAND) improve their visual speed of processing (SOP), a researcher ...
- This ‘new’ strain of HIV is actually a good thingon November 11, 2019 at 8:21 am
Many outlets are reporting that scientists have spotted a new strain of HIV for the first time in almost two decades. It would be reasonable to assume this was bad news. It certainly sounds as if the ...
- ‘Geography is a problem’: slowing the silent spread of HIV in the Amazonon November 10, 2019 at 11:00 pm
Detection and treatment of HIV and Aids in Loreto is compounded by the dispersed nature of the population. Photograph: Rodrigo Abd/AP As the serpentine Amazon river meanders through a sea of jungle, a ...
- Kansas man claims he was fired from a restaurant because he has HIVon November 10, 2019 at 3:05 pm
A man is suing a Kansas restaurant, claiming he was fired because he has HIV-- which would be a violation of the Americans with Disabilities Act. Armando Gutierrez was a server at a Big Biscuit ...
- Groundbreaking HIV vaccine design strategy shows promise in proof-of-principle testson November 10, 2019 at 1:29 pm
The new vaccine strategy centers on stimulating the immune system to produce broadly neutralizing antibodies (bnAbs) against HIV. These special antibodies are capable of neutralizing many different ...
via Google News and Bing News